Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Another Record-High Graduation Success Rate For UNC Student-Athletes
For the sixth consecutive year, UNC student-athletes established a record-high multi-year graduation rate as reported in the NCAA's annual Graduation Success Rates. The overall student-athlete...
Fri Nov 21, 2025

Carolina Insider Podcast: UNC Football hosts Duke, Basketball recap, Dan Shulman, Dr. Wesley Burks
Jones Angell and Adam Lucas preview UNC Football's matchup with Duke (7:04). Tar Heel Basketball took care of Navy and now heads to Florida for...
Fri Nov 21, 2025

Chansky’s Notebook: Sorry, We Miss You
Why do you think the Beat Duke Parade fizzled out? There may be a lot of reasons why college parades with whacky floats are things...
Wed Nov 19, 2025

Chapel Hill’s He’s Not Here Among The Athletic’s ‘Top 10 College Bars’ for 2025
A downtown Chapel Hill staple long known for its appeal to both UNC students, Tar Heel fans and visitors recently landed on a national list...
Wed Nov 19, 2025